ADMA Biologics' Aseptic Fill-Finish Machine Scores FDA Approval

• The FDA has approved ADMA Biologics Inc's (NASDAQ: ADMA) in-house aseptic fill-finish machine, the VanRx SA25.

• Related Content: ADMA Biologics Stock Gains On FDA Approval For Plasma Collection Facility.

• With the VanRx operational, the Company expects a meaningful improvement in gross margins, enhanced patient supply consistency, accelerated inventory production cycle times, and increased control and visibility of commercial product lot releases.

• The approval of the VanRx will also provide ADMA with the opportunity to onboard new fill-finish contract manufacturing opportunities with third parties.

• The VanRx fill-finish machine utilizes a closed isolator design that removes human interventions and provides safe drug products for patients.

• Related content: Benzinga's Full FDA Calendar.

• Price Action: ADMA shares are up 10.2% at $1.40 during the premarket session on the last check Wednesday.

See more from Benzinga

• Click here for options trades from Benzinga

• Perrigo Buys Consumer Self-Care Firm For .1B: Highlights

• Johnson & Johnson Plans COVID-19 Booster Shot Trial In South Africa: Bloomberg

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.